Liu Yang1, Junghee Kwon1, Yury Popov2, Gabriella B Gajdos1, Tamas Ordog1, Rolf A Brekken3, Debabrata Mukhopadhyay4, Detlef Schuppan2, Yan Bi1, Douglas Simonetto1, Vijay H Shah5. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 2. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 3. Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas. 4. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: shah.vijay@mayo.edu.
Abstract
BACKGROUND & AIMS: Vascular endothelial growth factor (VEGF)-induced angiogenesis is implicated in fibrogenesis and portal hypertension. However, the function of VEGF in fibrosis resolution has not been explored. METHODS: We developed a cholecystojejunostomy procedure to reconstruct biliary flow after bile duct ligation in C57BL/6 mice to generate a model of fibrosis resolution. These mice were then given injections of VEGF-neutralizing (mcr84) or control antibodies, and other mice received an adenovirus that expressed mouse VEGF or a control vector. The procedure was also performed on macrophage fas-induced apoptosis mice, in which macrophages can be selectively depleted. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, vascular permeability, real-time polymerase chain reaction, and flow cytometry assays. RESULTS: VEGF-neutralizing antibodies prevented development of fibrosis but also disrupted hepatic tissue repair and fibrosis resolution. During fibrosis resolution, VEGF inhibition impaired liver sinusoidal permeability, which was associated with reduced monocyte migration, adhesion, and infiltration of fibrotic liver. Scar-associated macrophages contributed to this process by producing the chemokine (C-X-C motif) ligand 9 (CXCL9) and matrix metalloproteinase 13. Resolution of fibrosis was impaired in macrophage fas-induced apoptosis mice but increased after overexpression of CXCL9. CONCLUSIONS: In a mouse model of liver fibrosis resolution, VEGF promoted fibrogenesis, but was also required for hepatic tissue repair and fibrosis resolution. We observed that VEGF regulates vascular permeability, monocyte infiltration, and scar-associated macrophages function.
BACKGROUND & AIMS:Vascular endothelial growth factor (VEGF)-induced angiogenesis is implicated in fibrogenesis and portal hypertension. However, the function of VEGF in fibrosis resolution has not been explored. METHODS: We developed a cholecystojejunostomy procedure to reconstruct biliary flow after bile duct ligation in C57BL/6 mice to generate a model of fibrosis resolution. These mice were then given injections of VEGF-neutralizing (mcr84) or control antibodies, and other mice received an adenovirus that expressed mouseVEGF or a control vector. The procedure was also performed on macrophage fas-induced apoptosis mice, in which macrophages can be selectively depleted. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, vascular permeability, real-time polymerase chain reaction, and flow cytometry assays. RESULTS:VEGF-neutralizing antibodies prevented development of fibrosis but also disrupted hepatic tissue repair and fibrosis resolution. During fibrosis resolution, VEGF inhibition impaired liver sinusoidal permeability, which was associated with reduced monocyte migration, adhesion, and infiltration of fibrotic liver. Scar-associated macrophages contributed to this process by producing the chemokine (C-X-C motif) ligand 9 (CXCL9) and matrix metalloproteinase 13. Resolution of fibrosis was impaired in macrophage fas-induced apoptosis mice but increased after overexpression of CXCL9. CONCLUSIONS: In a mouse model of liver fibrosis resolution, VEGF promoted fibrogenesis, but was also required for hepatic tissue repair and fibrosis resolution. We observed that VEGF regulates vascular permeability, monocyte infiltration, and scar-associated macrophages function.
Authors: Jeremy S Duffield; Stuart J Forbes; Christothea M Constandinou; Spike Clay; Marina Partolina; Srilatha Vuthoori; Shengji Wu; Richard Lang; John P Iredale Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: Robert M Strieter; Marie D Burdick; Brigitte N Gomperts; John A Belperio; Michael P Keane Journal: Cytokine Growth Factor Rev Date: 2005-07-19 Impact factor: 7.638
Authors: Liu Yang; Che-Chang Chan; Oh-Sang Kwon; Songling Liu; Jason McGhee; Stephen A Stimpson; Lihong Z Chen; W Wallace Harrington; William T Symonds; Don C Rockey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-06-22 Impact factor: 4.052
Authors: Claus Cursiefen; Lu Chen; Leonardo P Borges; David Jackson; Jingtai Cao; Czeslaw Radziejewski; Patricia A D'Amore; M Reza Dana; Stanley J Wiegand; J Wayne Streilein Journal: J Clin Invest Date: 2004-04 Impact factor: 14.808
Authors: J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur Journal: J Clin Invest Date: 1998-08-01 Impact factor: 14.808
Authors: Chun Geun Lee; Holger Link; Peter Baluk; Robert J Homer; Svetlana Chapoval; Vineet Bhandari; Min Jong Kang; Lauren Cohn; Yoon Keun Kim; Donald M McDonald; Jack A Elias Journal: Nat Med Date: 2004-09-19 Impact factor: 53.440
Authors: Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy Journal: J Leukoc Biol Date: 2014-11-14 Impact factor: 4.962
Authors: Nathalie H Urrunaga; Ravirajsinh N Jadeja; Vikrant Rachakonda; Daniel Ahmad; Leon P McLean; Kunrong Cheng; Vijay Shah; William S Twaddell; Jean-Pierre Raufman; Sandeep Khurana Journal: Free Radic Biol Med Date: 2014-10-31 Impact factor: 7.376